This site is intended for a global audience
Contact Us

Why Epilepsy Care Must Move Beyond Seizure Control to Broader Patient Needs

Derrick Lenz, Senior Vice President, U.S. Franchise Head, Epilepsy & Movement Disorders

When I think about the work we do at Jazz Pharmaceuticals, I find myself reflecting on the patients and families navigating the daily realities of rare and severe, treatment-resistant epilepsies. Our work is guided by a simple conviction: every person living with a complex neurological condition, and those who care for them, deserve the opportunity to live their life as fully as possible. These stories inspire us to look beyond seizures to what else matters in their daily lives.

Moving Beyond Seizure Control to Life Outcomes

Historically, success in epilepsy care was measured through the singular lens of reducing the frequency of seizures. While decreasing seizures will always be important, true progress requires going further. The hallmark of developmental and epileptic encephalopathies, including Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex, is how the conditions impact patients beyond seizure burden. These conditions affect cognition, communication, behavior and sleep, contributing to the overall complexity of disease management.1

Listening closely to patients, caregivers and clinicians has reinforced that treatments should address the broader impact of these conditions. This has taught us that a comprehensive assessment of treatment benefit should consider outcomes beyond seizure frequency.

In addition to addressing these life outcomes, to better serve the epilepsy community we must also acknowledge a critical and underrecognized challenge: the adult diagnostic gap. Although severe epilepsy syndromes are often viewed as pediatric conditions, they are lifelong.2 Many adults, particularly those in long-term care or transitioning from pediatric settings, lack a formal, syndrome-specific diagnosis decades after seizure onset. Without an accurate or updated diagnosis, this can limit opportunities for optimized management, research participation and access to clinical advances in genetically defined epilepsies that might offer syndrome-specific treatment approaches.

Empowering clinicians with the education and tools needed to identify these conditions across all age groups is essential to expanding care and closing this gap. Jazz’s award-winning See A Seizure campaign demonstrates how we are putting our community commitment into action. Through visual simulations of real-world seizure representations, the initiative helps identify subtle seizure activity that might otherwise be overlooked.

Innovation Guided by the Community

Meaningful progress requires us to continuously redefine what’s possible. By listening to patients, care teams and leading experts, we can better understand community needs and use what we learn to shape our research priorities.

Together these community insights guide our early-stage research, including better understanding the underlying biology for specific genetic and syndrome-specific diagnoses to develop precision therapies, while recognizing the need for treatment options which offer greater flexibility, administration options, and age-appropriate delivery throughout patients’ lives. With more specific diagnoses and treatment options, clinicians can tailor care and guide management to improve outcomes and address their patients holistically.

Every day, we stand alongside the epilepsy community. By uniting scientific rigor with empathy, we’ll continue to listen, innovate and advocate to elevate standards of care and redefine what is possible for people living with rare and severe epilepsies, across every stage of life.

  1. Dang A. Real-World Evidence: A Primer. Pharmaceut Med. 2023;37(1):25-36. doi: 10.1007/s40290-022-00456-6 
  2. LGS Diagnosis Deep Dive; HCP ATU W15 (9-25) (In 2027-2029 Strategic Plan: Epidiolex).